Newton Fund - Graphene biosensor for point of care hepatitis diagnostics
Lead Participant:
BIOVICI LIMITED
Abstract
Exceptional electronic properties, surface sensitivity and selectivity, make graphene ideal for sensor applications. Novel, generic, real-time monitoring sensor technology, based on chemically modified graphene channels, will be demonstrated for the detection of salivary / serum hepatitis biomakers.
The project will develop an innovative graphene based point-of-care sensor platform for the early detection of multiple hepatitis biomarkers, for simultaneous monitoring of hepatitis A, B and C. The generic POC platform will enable more efficient & effective healthcare delivery and improved health outcomes for patients. Graphene sensors will be fabricated on full wafers and functionalised using a novel chemical and biochemical modification techniques. Graphene sensor devices will be integrated with printed electronics and microfluidics
to form a self contained packaged, single-use sensor. The sensor platform can also be adapted for the detection of other disease markers including, stroke, heart disease, cancer and dementia. A complete disposable strip and electronic reader system, akin to blood glucose monitoring kits, will be developed.
The project will develop an innovative graphene based point-of-care sensor platform for the early detection of multiple hepatitis biomarkers, for simultaneous monitoring of hepatitis A, B and C. The generic POC platform will enable more efficient & effective healthcare delivery and improved health outcomes for patients. Graphene sensors will be fabricated on full wafers and functionalised using a novel chemical and biochemical modification techniques. Graphene sensor devices will be integrated with printed electronics and microfluidics
to form a self contained packaged, single-use sensor. The sensor platform can also be adapted for the detection of other disease markers including, stroke, heart disease, cancer and dementia. A complete disposable strip and electronic reader system, akin to blood glucose monitoring kits, will be developed.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
BIOVICI LIMITED | £219,337 | £ 153,536 |
  | ||
Participant |
||
NPL MANAGEMENT LIMITED | £219,615 | £ 109,808 |
SWANSEA UNIVERSITY | £355,467 | £ 355,467 |
INNOVATE UK | ||
NPL MANAGEMENT LIMITED |
People |
ORCID iD |
Gareth Morgan (Project Manager) |